Shareholders back Respiri in heavily oversubscribed share purchase plan

Wheezo asthma diagnostic and monitoring technology

Respiri has developed its wheezo device and eHealth software as a service technology to support the management of respiratory health.

Machine learning is employed to detect wheeze via the wheezo device and app. Wheeze is a typical asthma symptom and is common in other respiratory disorders.

The technology is then able to provide personalised feedback and education based on a user’s personal health data, which is also correlated with environmental factors.

If necessary, the data can be shared with health professionals.

The technology has secured both CE Mark and Therapeutic Goods Administration approval for use in the EU and Australia with US Food and Drug Administration clearance anticipated before the end of the year.

As part of its progress to full scale manufacturing and commercialisation, Respiri has secured telehealth partnerships with Phenix Health and Practice Innovators.

You can view the full article here: https://smallcaps.com.au/shareholders-back-respiri-heavily-oversubscribed-share-purchase-plan/